PLPL - Plandaí Biotechnology, Inc.PLPL Company Description
Plandaí Biotechnology, Inc. (OTCQB: PLPL): Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.
Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.comPLPL Products and BenefitsPhytofare™
"BIOAVAILABILITY" can be defined as a measurement of the amount of compound absorbed into the bloodstream.
In the market today, green tea high purity EGCG extracts, with an average selling price of $500/kg, have poor bioavailability of between 1-10%. Plandaí proprietary plant extracts has shown, in published studies, to have increased bioavailability. We believe through our studies that this is between 60-80%, far exceeding anything currently available today.
Our extracts include but are not limited to, gallate catechins from green tea, (catechin gallate (CG),epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene)from tomatoes, as well as citrus bioflavonoids and limonoids. Furthermore, Plandaí's gallate catechin extract will be the active ingredient in formulated products supporting weight loss, antiaging, the lowering of blood cholesterol, the regulation of high blood pressure and controlling diabetes 1 and 2.
This means, that Plandaí's extracts deliver a more meaningful and beneficial dose at highly competitive prices to the consumer, in wellness terms
The Northern American and European natural extracts market are emerging and in a state of intense competition. The shift towards natural ingredients is driving the expansion of the natural extracts market. Among the flurry of ingredients competing in the natural extracts market, green tea extracts is a pioneer and one of the most prominent success stories. (Frost & Sullivan Research, 2011)Current Projects
Plandaí Biotechnology, Inc., through its wholly owned subsidiaries, farms over 7500 acres of luscious land in the Mpumalanga province of South Africa.
It farms a whole fruit basket of produce which it uses in its creation of highly bioavailable extracts, ranging from citrus to avocado pears to most notably over 2000 acres of tea.
The tea plant, Camellia Sinensis, is an evergreen shrub or tree and can grow to heights of 30ft though for cultivation is pruned to heights of 2-5ft.
Farming in South Africa is like no other country in the world and because of this we needed to make sure that we stacked the deck in our favour and employed only the best as ever y step of the product creation pathway is critical. With that in mind, our farming team has over 100 years of experience in managing farms in Southern Africa.Green Tea Project
Green tea is one of the most widely consumed beverages in the world, second only to water, and its medicinal properties have been widely explored.
The tea plant, Camellia Sinensis, is a member if the Theaceae family and black, oolong and green tea are produced from its leaves.
It's an evergreen shrub or tree and can grow to heights of 30ft though for cultivation is pruned to heights of 2-5ft.Gallate Catechin Extract Project
Polyphenols found in tea are more commonly known as flavanols or catechins and comprise 30-40% of the extractable solids of dried green tea leaves. There are 8 catechins in green tea and of those 8 the gallate catechins are;
Catechin gallate (CG)
A number of the catechin polyphenols that are abundant in tea are reputed to have pharmacologically active properties. Within the plant, catechins are purported to be involved in the defence against pathogens, including insects, bacteria, fungi and viruses. Protection against bacterial and viral infection has also been observed against human pathogens as well as a plethora of other heath parameters. Clinical immunology 2010; 137,347-356
Unlike most green tea extracts on the market which focus on selling EGCG, which is the dominant gallate catechin, Plandaí Biotechnology extract, Phytofare™-Gallate Catechin extract (GCE), utilizes all four gallate catechins so as to benefit from their synergistic qualities as when a single phytochemical is isolated as an ingredient for a nutraceutical or pharmaceutical related product the synergistic activities created by the presence of the whole phytochemical is lost and therefore bioavailability or absorption is reduced.
By ingesting catechins individually, irrespective of the purity, van Amelsvoort et al. demonstrated that the galloyation of the catechins EGCG, ECG, CG and GCG, whilst having higher activities than those catechins without the galloyl moiety (EGC and CG) have reduced their absorption and are the least absorbed.http://www.plandaibiotech.com/images/senteeko-2013-tea3.jpgResearch and DevelopmentCitrus
Citrus is recognized as one of the most healthful components of the human diet. Much of the contribution of citrus in human health and nutrition is attributed to secondary metabolites present in the fruit including antioxidants, (ascorbic acid, flavanones, simple phenolics, carotenoids), folate and pectin.
From 2006 through 2009 the company undertook extensive documented citrus fruit studies with Sunkist growers at the fruit juice processing facilities in Ontario and Tipton, California to recover pectin, bioflavonoids, limonoids and limonene. Scientific validation was undertaken by USDA and Chromadex Inc. These investigations included considerable research of Sunkist production of FDA pharmaceutical extracts during the 1950 -1960’s of citrus bioflavonoids, limonoids, pectin, limonene and vitamin C. Furthermore, 104 Sunkist clinical publications on citrus bioflavonoids delivered conclusive evidence of citrus bioflavonoid efficacy in blood, vascular and capillary studies.
Based on these findings, the company second phase project is to process lemon fruits during the period the tea business is dormant and to recover a number of specific botanical extracts as active ingredients for
THE TREATMENT OF INFLAMMATORY CONDITIONS WITH CITRUS BIOFLAVONOIDS
The corticosteroid blood level is enhanced
Treatment of rheumatic fever is improved by inclusion of citrus bioflavonoids in the therapeutic regimen.
The frequency and severity of rheumatic epistaxis (nose-bled) is diminished by citrus bioflavonoids
Maintenance of Capillary Integrity
Athletic Injuries and Citrus Bioflavonoid Therapy
The Common Cold
A total of eleven studies were reviewed on the use of citrus bioflavonoids (Hesperidin) and ascorbic acid in the treatment of upper respiratory infections. Clinical trials Saylor (1956) with ninety nine patients with allergic and vasomotor rhinitis, (which so closely resembles the common cold with it nasal symptoms) observed complete or partial relief from 69% using Hesperidin, Chalcone and Sodium in daily divided doses.
WL Macon. Journal of Industry, Medicine and Surgery November 1956. A total of one hundred and twenty one persons who met rigid qualifications as having a common cold were studied with sixty two receiving a combination of lemon-orange flavonate glycoside, and ascorbic acid; and the other fifty nine receiving aspirin, phenacetin and caffeine, a well known palliative for the cold.
A total of forty six patients (74.2%) reported on the second day of taking the medication that they achieved complete or substantial relief when taking the bioflavonoid combination. In comparison only 30% (50.9%) taking ACP’s, the best known palliative obtained similar relief.Tomatoes
Farming and Recovery from tomatoes of Bioavailable Lycopene, phytoene and phytofluene extracts
Lycopene, phytoene and phytofluene are carotenoid pigments, found in tomatoes and other red fruits. They are natural fat-soluble pigments (red, in the case of lycopene) which are synthesized by some plants and micro-organisms but not by animals. They serve as an accessory light-gathering pigment and also aid in the protection of these organisms against the toxic effects of oxygen and light.
Lycopene, phytoene and phytofluene are the most common antioxidant carotenoids in the human body which are poorly absorbed by the human body. They are naturally present in human plasma and tissues in higher concentrations than the other carotenoids. Its levels are affected by several biological and lifestyle factors. Because of its lypophilic nature, its concentrates in low-density and very-low-density lipoprotein fractions of the serum and are also found to concentrate in the adrenal, liver, testes, and prostate. However, unlike other carotenoids, lycopene, phytoene and phytofluene levels in serum or tissues do not correlate well with overall intake of fruits and vegetables.
Cardiovascular diseases, along with cancer, are the main mortality causes in Europe and other developed countries. Strong correlative evidence suggests that lycopene may provide important protection against cardiovascular diseases and cancer. However the missing links in the chain are bioavailability, metabolism, and molecular mechanisms of biological activities that are still unknown. http://www.lycocard.com
In published studies conducted with tomato growers of California between 2006 -2009, and supported by scientific analysis and investigations by USDA, Chromadex Inc., Craft Laboratories and other specialized laboratories, Phytofare™ carotenoid extracts showed considerable evidence of increased accessibility of lycopene, phytoene and phytofluene to extraction procedures on tomato, while changing the stereoisomeric profile of the carotenoids to one that was highly bioavailable and therefore more beneficial to consumers.Active ingredient for novel anti-malaria-drug
Most efforts to design vaccine interventions against malaria has been focused on the blood stage of the parasite, which is responsible for the symptoms of the disease; and it is only now that a number of successful studies with gallate catechins have provides a good scientific rationale to develop a preventive drug against the pre-erythrocyte stages of the malaria parasite.
It is in the specific target area that a bioavailable green tea gallate catechin extract has been identified as the potential active ingredient of inhibiting the hexose uptake processes in infected erythrocytes; which is the primary mechanism of their anti-malarial activity and may involve interaction with alternative higher affinity target/s. Gallate catechins are able to inhibit motility and cause cytotoxcity through the form of several hydrogen structures and ionic bonds with proteins and thereby modulating their 3D structure. It has been shown that gallate catechins bind to adhesion molecules on the parasite surface and this impairs gliding, leading to an inactivation of the surface proteins and rendering the parasites immotile. In published in-vitro and animal model studies, gallate catechins have shown inhibiting qualities and anti-malaria properties.
Plasmodium sporozoites are the forms of the malaria parasite injected into the host during a blood meal of the mosquito; and they are then deposited within the skin, where they can move at a speed of around 1 µm/s. Some sporozoites can enter blood vessels and are transported to the liver, where they invade hepatocytes to differentiate into red blood cell invading merozoites.
Gallate catechins bind to the intercellular adhesion molecule 1 (ICAM 1) on the endothelium thus blocking the adhesion of Plasmodium infected erythrocytes.
Inhibits Plasmodium falciparum growth in vitro and potentiates the anti-malarial effects of artemisinin.
Mechanism of inhibition of an enoyl-acyl carrier protein reductase of Plasmodium falciparum, resulting in the inhibition of the fatty acid biosynthesis in the parasite.
Malaria Journal Slavic et al. Malaria Journal 2011, 10:165
In 2012, Plandai Biotechnology is scheduled to undertake in-vitro and animal studies to validate its extract, Phytofare™-GCE, as an active ingredient for novel anti-malaria drugs. PLPL Key Company ManagementRoger Duffield - President & CEO
Roger Duffield has a significant background in the development and management of start-ups, private and public companies, especially in the United States, Europe and South Africa. His previous contributions in the United States public sector include Klinair Technologies Inc. and Rhombic Inc. relating to energy and hydrocarbon technologies. Through his extensive involvement with research and development programs with a number of academic institutions, including Penn State, University of Southern California, University of Washington, and the University of Limerick, Ireland, he was awarded two honorary Russian doctorates in Natural Sciences from the University of Moscow and Novosibirsk. In 2001 the Foundation for International Services, California recognized a degree in BSc. Chemical Engineering.
In 2001 he co-founded Global Energy Solutions Corporation Limited, Dublin, Ireland, recently acquired by Plandaí Biotechnology, Inc., and in 2003, the USA-based Research Company, CRS Technologies Inc. Mr. Duffield now heads this group of companies specializing, through private and public investment in the farming and recovery of highly valuable botanical extracts with unique characteristics.Callum Baylis-Duffield - Vice President
Mr. Callum Baylis-Duffield is a graduate in International Business with French (BA Hons) from the University of the West of England. From 2007-2010, he was employed by Johnson and Johnson UK as a marketing & sales manager of a proprietary surgical device. Since 2010 he has been exclusively employed by Global Energy Solutions as the Director of Marketing and Sales and for the past 18 months has been based in South Africa where he has been integral to bringing the proprietary extract to market.
Mr Baylis-Duffield has been involved with the research and development of the Plandaí’s proprietary emulsions since 2004 and has worked extensively with the USA scientific team.PLPL Contact Info
Plandaí Biotechnology, Inc.
2226 Eastlake Avenue East
Seattle, WA 98102
Email: firstname.lastname@example.orgPLPL SEC Filingshttp://www.otcmarkets.com/stock/PLPL/filingsPLPL Headlineshttp://finance.yahoo.com/q/h?s=PLPL+Headlines
Investigate more about PLPL @ http://www.otcmarkets.com/stock/PLPL/quote
for more due diligence.